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ABSTRACT
Objectives: Abnormal uterine bleeding (AUB) impacts
women’s health-related quality of life (HRQoL) and puts a
heavy economic burden on society. To date, this burden has
not been systematically studied. We conducted a systematic
review of the medical literature to evaluate the impact of
AUB on HRQoL and to quantify the economic burden of
AUB from a societal perspective.
Methods: We searched the PubMed and Cochrane data-
bases, and article bibliographies for the period up to July
2005. Teams of two reviewers independently abstracted data
from studies that reported outcomes of interest: prevalence,
HRQoL, work impairment, and health-care utilization and
costs associated with AUB.
Results: The search yielded 1009 English-language articles.
Ninety-eight studies (including randomized controlled trials,
observational studies, and reviews) that met the inclusion and
exclusion criteria underwent a full-text review. The preva-
lence of AUB among women of reproductive age ranged
from 10% to 30%. The HRQoL scores from the 36-item
Short-Form Health Survey Questionnaire (SF-36) suggested
that women with AUB have HRQoL below the 25th percen-
tile of that for the general female population within a similar
age range. The conservatively estimated annual direct and
indirect economic costs of AUB were approximately $1
billion and $12 billion, respectively. These ﬁgures do not
account for intangible costs and productivity loss due to
presenteeism.
Conclusions: The burden of AUB needs further and more
thorough investigation. Additional research should prospec-
tively evaluate the impact of AUB and the value of treatment
provided to help guide future health resource allocation and
clinical decision-making.
Keywords: abnormal uterine bleeding, health-care costs and
utilization, health-related quality of life, systematic review,
work impairment.
Introduction
Abnormal uterine bleeding (AUB) is a common gyne-
cologic disorder affecting women of reproductive age.
AUB is deﬁned as change in frequency of menses,
duration of ﬂow, or amount of blood loss. AUB
includes heavy menstrual bleeding (i.e., menorrhagia)
and can be due to a functional abnormality (e.g., dys-
functional uterine bleeding [DUB]), organic abnor-
mality (e.g., ﬁbroids), or systemic disorder (e.g., von
Willebrand disease) [1,2]. The commonly cited epide-
miological information related to AUB is that up to
30% of reproductive age women suffer from menor-
rhagia [1].
The treatment for AUB includes both medical thera-
pies and surgical procedures. Medical therapies are
recommended as ﬁrst-line treatments [3] and include
oral contraceptives (OCs), progestins, tranexamic
acid, mefenamic acid, danazol, and gonadotropin-
releasing hormone analogs. Women seeking treat-
ment for AUB who also require contraception have a
choice of OCs, long-acting progestogens, or the
levonorgestrel-releasing intrauterine system (LNG-
IUS) [1,4–9]. Hysterectomy is an invasive surgical
option that usually is recommended only after other
therapies for AUB have failed and for women who do
not wish to retain their fertility. Endometrial ablation
techniques, including ﬁrst-generation (transcervical
resection of the endometrium [TCRE], roller-ball,
and laser ablation) and second-generation (thermal
balloon, microwave, radiofrequency, cryoablation,
and hydrothermal ablation), are less invasive surgical
alternatives to hysterectomy [10,11].
Mortality and serious complications from AUB are
extremely uncommon. The true burden of AUB is best
characterized by its impact on health-related quality of
life (HRQoL), as well as health-care utilization, direct
costs, and indirect costs (e.g., work productivity loss).
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Nevertheless, no study has systematically described
the burden of AUB in terms of these outcomes. The
Global Burden of Disease Project, conducted as a col-
laboration of the World Health Organization, Harvard
School of Public Health, and the World Bank, due to
resource constraints did not include menstrual disor-
ders (including AUB) among the 483 disabling diseases
and injuries analyzed [12–14]. To ﬁll this knowledge
gap, we conducted a systematic review to characterize
how AUB impacts HRQoL, work impairment, and
health-care costs and utilization. Furthermore, we
reviewed the literature that quantiﬁed the prevalence
of AUB.
Methods
Literature Search and Review
We conducted a systematic review of the published
literature to identify studies on AUB that reported any
of our four outcomes of interest: 1) prevalence; 2)
HRQoL; 3) health-care utilization and direct treat-
ment cost; and 4) work impairment and indirect cost.
We searched the PubMed and Cochrane databases for
English-language articles published from 1980 to July
2005. MeSH terms and keywords were used in
searches that combined disease conditions (AUB, DUB,
menorrhagia, heavy menstrual bleeding) with out-
comes of interest (prevalence, epidemiology, epidemio-
logic, quality of life, functioning, impairment, health
services, utilization, care-seeking behavior, treatment-
seeking behavior, burden, economics, economic, costs,
cost, productivity, absenteeism, presenteeism, work
impairment). We did not search for abstracts, posters,
or conference proceedings.
Titles and abstracts were reviewed using explicit
inclusion criteria to identify articles pertaining to our
search objective. We excluded letters and case reports.
After title and abstract review, we conducted a full-text
review and included all studies that reported outcomes
of interest. For studies on HRQoL, only those studies
that used reportedly validated HRQoL instrument(s)
were candidates for full-text review. During full-text
review, we also searched article bibliographies to iden-
tify additional studies for full-text review.
At each stage of the review process, two reviewers
conducted independent appraisals of the title/abstract
or article and resolved disagreements by consensus.
Inter-rater reliability was tested on a 10% sample, with
Kappa values greater than 0.70 at each stage of the
review.
Data from each accepted article were abstracted
into an evidence table that detailed key information,
including study design, sample size, study population
characteristics, outcomes, and conclusions. Data were
analyzed separately for each of the four outcomes of
interest.
Data Synthesis
We assessed the prevalence qualitatively because the
studies were few and the data were heterogeneous,
thus precluding meta-analyses.
We assessed the impact of AUB on HRQoL either
qualitatively or quantitatively based on the availability
and heterogeneity of the data. We quantitatively evalu-
ated studies that used the 36-item Short-Form Health
Survey Questionnaire (SF-36), which is the most com-
monly used generic HRQoL instrument for various
disease conditions including menorrhagia [15–18].
SF-36 includes 36 items that measure eight dimensions
of HRQoL: physical functioning, physical role func-
tioning, bodily pain, general health, energy/vitality,
social functioning, emotional role functioning, and
mental health. We used a conservative random-effects
meta-analytic model to pool SF-36 scores for each of
the eight domains. We then compared the pooled esti-
mates with the US population normative values for
women aged from 18 to 54 years, which was calcu-
lated as the weighted average across age groups [19].
We qualitatively assessed the rest of the studies on
HRQoL.
We also estimated the total direct and indirect eco-
nomic burden due to AUB from a societal perspective
and at the population level. We based our estimate on
the disease prevalence, health-care utilization, treat-
ment costs, and indirect cost per person as identiﬁed
from our literature review. Direct economic burden
included treatment costs associated with AUB, while
indirect economic burden included productivity loss
due to work impairment, speciﬁcally absenteeism (i.e.,
productivity loss because of absence from work) and
presenteeism (i.e., productivity loss while at work). We
chose the lower and upper bound of each variable to
provide the most conservative as well as a liberal eco-
nomic estimate.
Results
Literature Review
Our initial search strategy yielded 1009 publications;
79 studies met our title/abstract inclusion criteria and
underwent a full-text review. Bibliographic searches
yielded 15 additional studies for full-text review. Of
these 94 articles, 20 were reviews and their informa-
tion served as background for this systematic review.
The remaining 74 articles underwent data abstraction
for the following outcomes: prevalence, 6; HRQoL,
34; health-care utilization, 30 (health-care utilization
only, 25; the rest of the 30 studies also addressed
HRQoL); and work impairment, 4.
Prevalence of AUB
Only six studies assessed prevalence of AUB; preva-
lence varied considerably depending on how blood loss
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was measured. Data from population-based studies,
conducted several decades ago and including samples
of fewer than 1000 women, suggested that approxi-
mately 10% of reproductive-aged women had objec-
tive evidence of menorrhagia (i.e., menstrual blood
loss more than 80 ml) [20,21]. In contrast, studies
based on self-reported information suggested that
approximately 30% of women of reproductive age
were afﬂicted with heavy menstrual bleeding [22–24].
The discrepancy in subjective and objective measures
of blood loss also was found in several other studies
[25,26].
A completely objective measure, such as extracting
hemoglobin from sanitary wear to assess blood loss
(i.e., alkaline hematin technique), usually is impracti-
cal outside of controlled research settings. A mandate
for objective assessment of blood loss may not be
appropriate because the amount of blood loss does not
fully predict women’s care-seeking behavior [27,28].
Most gynecologists (96%) indicated that they diag-
nosed menorrhagia based on women’s self-reported
symptoms of excessive menstrual bleeding [25]. The
pictorial blood loss assessment chart is a widely used
alternative to measure blood loss. This semiobjective
measure takes into account the number of items of
sanitary wear used and the degree of staining of each
item, and is easier to perform than the alkaline
hematin technique, yet yields more objective results
than self-reporting [29].
Discordance also existed depending on who
assessed the condition. Gynecologists reported that
only 8% of their patients complained of menorrhagia;
this estimate is lower than the rate based on self-report
[25], which suggests that not all women seek treatment
for perceived menstrual disorders, among which AUB
would be prominent. One study reported that 57.1%
of patients who considered their symptoms as severe
were rated by their physicians as having only moderate
symptoms. Conversely, 28.7% of the patients report-
ing mild or moderate severity were diagnosed with
severe symptoms [30].
Health-Related Quality of Life
Impact of AUB on HRQoL. AUB has a broad impact
on HRQoL. Menorrhagia is the most common cause
of iron-deﬁciency anemia in the developed world.
Excessive menstrual bleeding (monthly blood loss in
excess of 60 ml) can deplete iron stores, which leads to
iron-deﬁciency anemia. Anemia may impact HRQoL
by manifesting as weakness, fatigue, unexplained
weight loss, mood swings, and impaired cognitive
functioning [31].
Table 1 lists the eight studies that provided SF-36
scores in all eight domains attributable to AUB (i.e.,
before a speciﬁed treatment) and thus were included in
the meta-analysis [32–39]. Two other studies also used
the SF-36, but provided only summary scores of the
physical and mental components and were excluded
from the meta-analysis [40,41]. All eight studies were
randomized controlled trials (RCTs), and only one
was conducted in the United States. For seven of the
studies, the mean age of the study population was
approximately 40 years; one study had a relatively
young population (mean age: 29 years) [38]. Each
study provided two sets of baseline SF-36 scores in all
eight domains (because each study involved two treat-
ments) and thus a total of 16 data points were avail-
able for the meta-analysis on each domain.
The results showed that women with AUB had
lower SF-36 scores for all eight subscales compared
with normative values for American women aged from
18 to 54 years. The most signiﬁcantly affected domains
were the physical role functioning and emotional role
functioning subscales, which focus on work productiv-
ity and other daily activities. For six of the eight sub-
scales, scores for women with AUB were below the
25th percentile of national norms. The biggest impact
was observed for the physical role functioning domain,
which was 23 points below the 25th percentile norms
(60.3 vs. 83.2) (Table 2).
Sixteen studies used other validated HRQoL instru-
ments, which measured the impact of AUB on various
aspects of women’s lives including sexual functioning,
depression, anxiety, irritability, psychosocial adjust-
ment, and personality [22,30,41–54]. Only four of
these studies were conducted in the United States, and
the mean age in most of the studies was approximately
40 years.
These studies showed that AUB affected sexual
functioning [30,41], was associated with psychological
morbidity [22,30,43–48,50,52–54], and affected
social, professional, and family life [30,45,46,49,51].
For example, Kuppermann et al. reported that in
women with AUB refractory to hormonal management
(mean age: 41.8 years), the sexual functioning scores
measured by the Medical Outcomes Study Sexual
Problems Scales were only 55–69 as compared with
100 (optimal functioning) [41]. Greenberg and
coworkers showed that mild-to-moderate neurotic
depression was found in 62% of women with AUB
referred to a gynecologic clinic [53]. Shaw et al. evalu-
ated the impacts of menorrhagia using a multiattribute
utility assessment tool. They found that the order of
the impacts of menorrhagia (from most important to
least important) was family life, physical health, work
life, psychological health, practical difﬁculties, and
social life [46].
Few studies expressed HRQoL as a preference or
utility measure. A preference measure represents the
value that one assigns to a health state (e.g., menor-
rhagia), typically on a scale from zero (representing
death) to one (representing perfect health); a score of
0.5 therefore is equivalent to a half year of perfect
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health. In one study, preference for menorrhagia was
solicited from the time trade-off technique, and it
yielded a median of 0.55 (range: 0–0.95) and a mean
of 0.5 (SE = 0.04) [55]. A generic instrument measur-
ing health outcomes developed by the EuroQol group
(i.e., the EQ-5D) is gaining favor as a measure of
utility. Table 3 lists the four studies that provided base-
line EQ-5D information regarding AUB; two studies
were for the same population but with different lengths
of follow-up [8,45,56,57]. The study conducted by
Hurskainen et al. showed that the EQ-5D scores in
women with AUB were signiﬁcantly lower than the
mean scores of Finnish or British women of the same
age, suggesting that AUB may lead to signiﬁcantly
worse health [45].
Impact of AUB treatment on HRQoL. HRQoL was
included as one of the outcomes in many studies evalu-
ating treatment for AUB [11,58–64]. Among the 34
identiﬁed studies, 22 studies also provided baseline
HRQoL information and thus were summarized in the
previous section. The additional 12 studies had similar
study characteristics as those for the 22 studies (i.e.,
most were conducted in European countries, and the
mean age of the study population was approximately
40 years).
Studies showed that both ﬁrst- and second-
generation endometrial ablation techniques signiﬁ-
cantly improved HRQoL [35–37,39,42,44,56,57,
65,66]. For example, the two most recently published
RCTs showed that various endometrial ablation
techniques including TCRE, microwave endometrial
ablation, bipolar radio frequency endometrial abla-
tion, and balloon endometrial ablation improved the
majority of the eight SF-36 health domains, achieving
SF-36 scores similar to those for the general popula-
tion over both short term and long term [37,39]. Use
of the LNG-IUS was associated with the improvements
in HRQoL that were very similar to those seen with
endometrial ablation techniques [67–69]. Hysterec-
tomy also signiﬁcantly improved HRQoL; its overall
effect was similar to that of LNG-IUS or ablation, but
may have been particularly effective at reducing bodily
pain commonly experienced by women awaiting
hysterectomy [8,41,45,47–51,54,70–74]. OCs, pro-
gestins, and other pharmacological therapies yielded
the least improvement in HRQoL among the AUB
treatments studied [30,32–34,38,40,75]. One review
concluded that there was insufﬁcient information on
outcomes of medical management to guide clinical
decision-making [76].
Health Services Utilization and Costs
Impact of AUB on health services utilization. In the
United States, AUB is associated with signiﬁcant utili-
zation of resources in various health-care sectors.
Women who reported heavier menstrual blood loss
were more likely to visit a physician (OR = 1.48,
P  0.01), to receive emergency room care (OR =
1.79, P  0.01), and to undergo a surgical procedure
(OR = 1.56,P  0.01) [77,78]. Data from theNational
Hospital Discharge Survey indicated that AUB contrib-
uted to more than 5 million hospitalizations, 2 million
Table 2 Impact of AUB on HRQoL: SF-36 subscale scores compared with the national norms (highest HRQoL = 100)
Physical
function
Role/
physical Pain
General
health Vitality
Social
function
Role/
emotional
Mental
health
National norms* 25th percentile 83.3 83.2 60.9 64.2 46.2 72.1 70.4 63.6
Mean 87.5 84.0 76.7 73.8 59.3 83.1 81.1 73.1
AUB Meta-analysis (random-effects) 82.1 60.3 58.8 69.9 43.9 66.1 62.3 62.4
*Source: SF-36 Health Survey Manual & Interpretation Guide.
AUB, abnormal uterine bleeding; HRQoL, health-related quality of life.
Table 3 Effects of AUB on HRQoL: studies reporting baseline EQ-5D scores
Reference
Author
(year)
Study
setting
Study
design
Study
population
(mean age)
Treatment
group (n)
Baseline EQ-5D scores: mean (SD)
Group 1 Group 2
[56] Hawe et al.
(2003)
UK RCT Women with
DUB (41.4 vs.
41.1)
Cavaterm (n = 34)
vs. endometrial laser
ablation (n = 33)
EQ-5D index: 0.78 (0.26)
EQ-5D vas: 77.3 (14.2)
EQ-5D index: 0.65 (0.31)
EQ-5D vas: 69.4 (18.0)
[57] Abbott et al.
(2003)
UK RCT Women with
DUB (40.5 vs.
40.5)
Cavaterm (n = 17)
vs. NovaSure
(n = 37)
EQ-5D index: 0.66 (0.34)
EQ-5D vas: 70.2 (25.8)
EQ-5D index: 0.71 (0.23)
EQ-5D vas: 75.7 (18.1)
[45] [8] Hurskainen
et al. (2001)
Finland RCT Women with
menorrhagia
(43.1 vs. 43.0)
LNG-IUS (n = 119)
vs. hysterectomy
(n = 117)
EQ-5D index:
0.76 (0.70–0.80)
EQ-5D index:
0.78 (0.70–0.80)
AUB, abnormal uterine bleeding; DUB, dysfunctional uterine bleeding; HRQoL, health-related quality of life; LNG-IUS, levonorgestrel-releasing intrauterine system; RCT,
randomized controlled trial.
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hysterectomies, and 20 million hospital days in the
United States between 1980 and 1992 [79]. From 1988
to 1990, AUB was the fourth most common gyneco-
logic cause for hospitalization, and 89% of those hos-
pitalized underwent surgery [80]. AUB accounted for
more than 3 million ambulatory care visits (mostly to
physician ofﬁces) annually from 1999 to 2000 [81] and
for more than 20% of all visits to obstetricians/
gynecologists [82].
Treatment utilization. No study reported the rate of
medical treatment in the United States. Clinical experts
suggest that physicians normally would recommend at
least 3 months of pharmaceutical therapy (e.g., OCs)
as initial treatment. The rate of endometrial ablation
also was rarely reported. In a study that analyzed data
from Colorado, Maryland, New Jersey, Connecticut,
New York, and Wisconsin, Farquhar et al. found that
the ratios of total number of hysterectomy to endome-
trial ablation ranged from 1 to 3.5 in 1997. Because of
the ﬁndings that over time the diffusion of endometrial
ablation has had minimal impact on the rate of hys-
terectomy, they concluded that endometrial ablation
was used as an adjunctive technology rather than a
substitute for hysterectomy [83].
Hysterectomy remained second only to cesarean
section as the most frequently performed major opera-
tion in the United States throughout the 1990s, with
rates of 5.44, 5.23, 5.39, 5.60, and 4.40 per 1000
women aged 16 years or older in 1991, 1993, 1995,
1997, and 1999, respectively [84–87]. AUB is a fre-
quently cited indication for hysterectomy and accounts
for as many as 25% of all hysterectomies [49,88]. A
study reported AUB as the main presenting problem in
at least half of all the hysterectomies reported [89].
Treatment costs. Numerous studies compared the
treatment costs of endometrial ablation with hysterec-
tomy. Nevertheless, direct comparisons of these costs
in absolute terms across studies were precluded by
variations across study settings, study populations,
year of reported cost, and cost components (e.g.,
whether or not direct or indirect costs were considered,
or whether or not ablation failure rates were factored).
Despite this heterogeneity, most studies suggested that
hysterectomy cost twice as much as ablation
[72,74,88,90–99].
In one randomized trial, the overall costs of LNG-
IUS when used to treat AUB were approximately three
times lower than for the hysterectomy group at 1 year
of follow-up (averaging $1529 vs. $4222 per person,
in 1996 US dollars) [45]. At 5 years of follow-up, the
discounted direct and indirect costs in the LNG-IUS
group remained substantially lower than in the hyster-
ectomy group ($2817 [95% CI: $2222–3530] per par-
ticipant vs. $4660 [95% CI: $4014–5180], in 2001 US
dollars) [8]. The cost of LNG-IUS also compared
favorably with the annual cost of available medical
treatments including ibuprofen, OCs, mefenamic acid,
progestin, tranexamic acid, Provera, and danazol
[100].
Estimated direct economic burden of AUB. Based on
the reported prevalence, utilization rate, and unit
costs, we estimated the total direct cost due to AUB
as approximately $1 billion annually (in 2005 US
dollars). This included the costs of physician visits,
drug therapy, and treatment with hysterectomy and
ablation. Cost for hysterectomy alone may have
accounted for approximately half of the total treat-
ment cost (Table 4).
The total annual cost of $1 billion is a very conser-
vative estimate because we took the lower end value
for each data element. For example, based on the
results of Farquhar et al. we estimated that approxi-
mately 35,714 ablations are performed annually
(Table 4). Nevertheless, in another study in our review,
Gurtcheff and Sharp estimated that approximately
194,000 endometrial ablation procedures were per-
formed through May 2003 using ThermaChoice,
NovaSure, Her Option, and HydroThermAblator
[101]. Based on their ﬁgures, after the number of years
these devices had been on the market through 2003
was taken into account, the expected average number
Table 4 Conservative estimation of the annual direct economic burden of AUB
Treatment Utilization Cost per person (2005 USD) Total costs (2005 USD)
GP visit 3 million 35* 105 million
Drug therapy 1.8 million† 146‡ 263 million
Hysterectomy 125,000§ 4538|| 567 million
Endometrial ablation 35,714¶ 1770# 63 million
Total 998 million
*CPT = 99212 [114,115].
†Calculation is based on 72 million women aged 15–49 years, multiplied by 10% prevalence rate of AUB, and 1/4 seeking treatment [22,89,116].
‡3 months of supply of OCs (Ortho-Novum) [3,117].
§The total annual 500,000 hysterectomies multiplied by 25% attributable to AUB.
||The sum of the physician fee of $881 (CPT = 58150, 58260, 58550) and hospitalization costs of $3657 (DRG = 359) [115,118].
¶Based on rate ratio of 3.5:1 between hysterectomy and ablation.
#The sum of the physician fee of $301 (CPT = 58353, 58563) and hospital outpatient service payment of $1469 [115,119].
AUB, abnormal uterine bleeding; GP, general practitioner.
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of ablation procedures per year would be 52,606.
Using this number, the total cost associated with
endometrial ablation will increase to approximately
$93 million per year. Furthermore, assuming a 30%
prevalence rate, the total cost for drug therapy will be
$789 million per year. Therefore, a less conservative
estimate of the total costs associated with AUB is
approximately $1.55 billion, a 55% increase from the
conservative estimate.
Work Impairment (Indirect Costs)
Impact of AUB on work impairment. Very few studies
have assessed the impact of AUB on work productivity.
Hurskainen et al. reported that among women with
objective evidence of menorrhagia, 20% reported
having missed work because of menorrhagia during
the previous 6 months [102]. Pron et al. suggested that
as many as 40% of women with ﬁbroids (80% of
whom reported heavy menstrual bleeding) reported
taking time off work in the previous year for ﬁbroid-
related reasons—often several days a month, particu-
larly around the time of menstruation [103]. Among
women needing surgical treatment for menorrhagia,
39% to 55% reportedly took time off work in the
previous 6 months [51].
Only one study reported indirect costs due to AUB.
Cote et al. estimated that heavy bleeders worked
3.6 weeks fewer per year than nonheavy bleeders.
They also estimated that the work loss from increased
blood ﬂow was $1692 annually per woman [104].
Nevertheless, their estimation only took into account
absenteeism, not presenteeism; therefore, productivity
loss attributable to AUB in their study may have been
substantially underestimated.
Estimated indirect economic burden of AUB. We esti-
mated the annual indirect cost attributable to AUB as
approximately $12 billion based on the conservative
estimate of the prevalence rate of AUB and the results
of Cote et al.’s study (7.2 million sufferers multiplied
by $1692, in 2005 US dollars). When we assumed a
prevalence rate of 30%, this number increased to $36
billion. The indirect costs exceeded the direct costs
attributable to AUB by 12-fold (conservative estimate)
and 23-fold (liberal estimate). For the same reason
mentioned earlier, the actual indirect cost estimate may
be higher when presenteeism is taken into account.
Discussion
Epidemiological studies suggested that approximately
10% to 30% of reproductive-aged women were
affected by menorrhagia. It is likely that the prevalence
of AUB, which is a broader clinical condition than
menorrhagia, could be higher than the estimated 10%
to 30%. Accurately estimating the prevalence of AUB
is a challenge because some of the diagnostic methods
are objective while others are subjective, and discor-
dance exists between how patients and physicians rate
severity of AUB symptoms. Studies suggested that sub-
jective measures are better than objective measures
in predicting women’s treatment-seeking behavior
[27,28]. Given that the studies employing subjective
measures reported higher prevalence rates, this means
that the direct and indirect economic burden of AUB
may settle at the upper bound of our estimation
instead of the conservative estimation. The true burden
of AUB relies on an accurate estimate of AUB preva-
lence; therefore, it is very important to conduct epide-
miologic studies using a standardized deﬁnition. Such
research will help establish the burden of AUB and
raise awareness for future policy and resource
planning.
We attempted to quantify the burden of AUB by
comparing scores from validated HRQoL instruments
with population norms, using the meta-analysis tech-
nique. Despite the criticism of using a generic HRQoL
instrument [15,16], the SF-36 assesses a breadth of
HRQoL variables that are important to all patients
and thus helps compare individuals with a given
disease with the general population or with individuals
with other diseases. We found that according to the
SF-36 results, health with AUB was below the 25th
percentile for the US general female population and
AUB affected mostly the domains that were directly
linked to the work productivity and daily activities.
We found only one study that quantiﬁed the costs
stemming from absenteeism, but no studies for presen-
teeism. In estimating the indirect economic burden of
AUB, these omitted costs (work loss due to presentee-
ism) could represent an important burden from the
perspectives of society. Therefore, the current estimate
of annual indirect costs could be a large underestima-
tion. In future research, a more thorough evaluation of
work impairment, with particular attention to presen-
teeism, is needed to assess the full impact of AUB.
There are certain issues regarding treatment utiliza-
tion in AUB. There is evidence suggesting both under-
treatment and overtreatment for AUB. Not all women
suffering from AUB sought or received appropriate
treatment. For example, studies suggested that only
approximately 25% of women who complained of
heavy menstrual bleeding actually sought health care
[22,89]. The mean duration of AUB symptoms ranged
from 3 to 9 years before treatment [38,67,69,98,105–
107]. On the other hand, there was evidence suggest-
ing that some of the hysterectomies performed to treat
AUB may have been unnecessary [108–110]. In one
study, one-third of women complaining of menor-
rhagia but without objective evidence of heavy men-
strual bleeding still underwent hysterectomy [110].
This overutilization may be reﬂected in the estimated
high proportion of costs associated with hysterectomy
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among the estimated annual direct treatment costs for
AUB. The high rate of hysterectomy for AUB may
indicate either that women are not fully informed
about the availability of the less invasive techniques or
that there is a lack of communication between patients
and their physicians, who greatly inﬂuence women’s
decision-making. Addressing these issues is likely to
impact the health-care utilization and costs associated
with AUB.
Studies have suggested that medical treatment with
LNG-IUS and surgical treatment with endometrial
ablation or hysterectomy can all signiﬁcantly improve
women’s HRQoL. Choosing among these treatments
may therefore depend on the relative cost-effectiveness
or cost-utility of each treatment. In addition, women’s
preference strongly predicts the actual treatment [109].
Many women may prefer procedures that are less
invasive than hysterectomy and would be willing to
undergo these procedures even if the chance of success
is relatively poor [34,111–113]. Studies are needed
to evaluate the cost-effectiveness and cost-utility of
various treatment options for AUB, and to reveal
women’s treatment preferences as less invasive options
become available. If disseminated appropriately, this
information is likely to help improve the quality of
care and reduce the economic burden of AUB on
payers and society.
We suggest that further research on AUB be directed
to the areas of epidemiology, health economics, health
services, and patient-reported outcomes. As awareness
for the burden of AUB becomes greater, policymakers,
clinicians, and patient advocacy groups are likely to
demand better information. Although our systematic
review reveals available literature in these various
areas, the data are highly random and disconnected,
thus contributing to low precision when quantifying
burden of illness. In order for future research to be
more useful, the deﬁnition of AUB needs to be stan-
dardized so that it can be easily applied to many types
of research (such as clinical trials, epidemiological
research, health services research, social science
research, etc.). Payers will need to understand AUB-
related resource utilization, predictors of utilization,
and preferences for different services to treat AUB.
Moreover, there is a need to understand the economic
value of existing and emerging therapies for managing
AUB to make better decisions regarding health-care
spending. Policymakers will also need to understand
the appropriateness of current utilization. Employers
may also be interested in understanding the impact of
AUB on work force productivity with particular atten-
tion to presenteeism.
Conclusion
Evaluation of the literature suggests that the preva-
lence of AUB is at least 10% to 30% among
reproductive-aged women. The impact of AUB encom-
passes all aspects of HRQoL, with six health domains
measured by SF-36 below the 25th percentile of the US
general female population. AUB may also cost the
society $1 billion to $1.55 billion in annual direct
treatment costs and $12 billion to $36 billion in
annual indirect costs. The public as well as policymak-
ers need to increase awareness of the impact of this
common benign gynecologic disorder. Addressing
issues such as better quantifying the burden of AUB
as well as evaluating and disseminating information
regarding the most cost-effective solutions will likely
result in positive economic, health, and social impact.
We thank Berlex Laboratories, NJ for providing ﬁnancial
support for this project.
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